Related Experiment Video

Updated: Mar 5, 2026

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.6K

Targeting Smoothened Sensitizes Gastric Cancer to Chemotherapy in Experimental Models

Huifa Ma1, Yongsheng Tian1, Xiangyang Yu2

  • 1Department of General Surgery, Tianjin Hospital, Tianjin, China (mainland).

Medical Science Monitor : International Medical Journal of Experimental and Clinical Research
|March 29, 2017
PubMed

Insights

Smoothened (SMO) receptor is highly expressed in paclitaxel-resistant gastric cancer. Inhibiting SMO with IPI-926 combined with paclitaxel shows promise for overcoming drug resistance in gastric tumors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • The Hedgehog pathway and its receptor, smoothened (SMO), are implicated in tumor progression.
  • The role of SMO in gastric cancer chemotherapy resistance remains largely unexplored.

Purpose of the Study:

  • To investigate the function of SMO in paclitaxel resistance in gastric cancer.
  • To evaluate SMO as a potential therapeutic target for overcoming chemotherapy resistance.

Main Methods:

  • Analysis of SMO expression in clinical gastric cancer samples and cell lines (424GC, AGS).
  • In vitro and in vivo studies using paclitaxel-resistant gastric cancer models.
  • Assessment of SMO inhibition using IPI-926 in combination therapy.

Main Results:

  • High SMO expression was observed in paclitaxel-resistant gastric cancer samples and cells.
  • Increased SMO expression promoted paclitaxel resistance by enhancing proliferation and inhibiting apoptosis.
  • Combined treatment with IPI-926 and paclitaxel reduced cell viability and controlled tumor growth.

Conclusions:

  • SMO is a key regulator of paclitaxel resistance in gastric cancer.
  • Targeting SMO presents a potential strategy to sensitize paclitaxel-resistant gastric tumors.

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.7K
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.3K

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
698
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
752